Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Non-interventional Observational Study of Pramipexole in Restless Legs Syndrome: Impact on Quality of Life

Completed

Conditions: Restless Legs Syndrome

First Posted Date: 2007-10-04

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2023

Registration Number: NCT00539461

Locations: 🇩🇪
Boehringer Ingelheim Investigational Site, Hellenthal, Germany

Observational Non-interventional Study (Anwendungsbeobachtung) With Telmisartan in High-risk Hypertensives

Completed

Conditions: Hypertension
Obesity

First Posted Date: 2007-10-04

Last Posted Date: 2013-11-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 5827

Registration Number: NCT00539487

Locations: 🇩🇪
Boehringer Ingelheim Investigational Site 2, Übach-Palenberg, Germany
🇩🇪
Boehringer Ingelheim Investigational Site 13, München, Germany
🇩🇪
Boehringer Ingelheim Investigational Site 15, München, Germany

and more 91 locations

Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPD

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium
Drug: Salmeterol
Drug: Ciclesonide high
Drug: Fluticasone
Drug: Placebo
Drug: Ciclesonide low

First Posted Date: 2007-09-26

Last Posted Date: 2014-05-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 103

Registration Number: NCT00535366

Locations: 🇧🇪
1249.1.32002 Boehringer Ingelheim Investigational Site, Hasselt, Belgium
🇧🇪
1249.1.32001 Boehringer Ingelheim Investigational Site, Gent, Belgium
🇳🇱
1249.1.31003 Boehringer Ingelheim Investigational Site, Harderwijk, Netherlands

and more 9 locations

Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2007-09-18

Last Posted Date: 2014-06-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 85

Registration Number: NCT00530920

Locations: 🇮🇹
1182.107.39001 Boehringer Ingelheim Investigational Site, Antella (fi), Italy
🇪🇸
1182.107.34001 Boehringer Ingelheim Investigational Site, Barcelona, Spain
🇪🇸
1182.107.34002 Boehringer Ingelheim Investigational Site, Barcelona, Spain

and more 9 locations

Observational Non-interventional Study (Anwendungsbeobachtung) With Aptivus® (Tipranavir) in HIV-infected Patients.

Completed

Conditions: HIV Infections

Interventions: Drug: Tipranavir
Drug: Ritonavir

First Posted Date: 2007-09-18

Last Posted Date: 2014-04-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 65

Registration Number: NCT00531206

Locations: 🇩🇪
Boehringer Ingelheim Investigational Site, Wuppertal, Germany

Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2007-09-18

Last Posted Date: 2013-12-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 344

Registration Number: NCT00530842

Locations: 🇦🇹
205.334.4309 Boehringer Ingelheim Investigational Site, Gänserndorf, Austria
🇩🇪
205.334.4904 Boehringer Ingelheim Investigational Site, Donaustauf, Germany
🇩🇪
205.334.4901 Boehringer Ingelheim Investigational Site, Großhansdorf, Germany

and more 39 locations

An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium Bromide
Drug: Placebo
Drug: BEA 2180 BR

First Posted Date: 2007-09-14

Last Posted Date: 2021-08-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2080

Registration Number: NCT00528996

Locations: 🇺🇸
1205.14.042 Boehringer Ingelheim Investigational Site, Berkeley, California, United States
🇺🇸
1205.14.046 Boehringer Ingelheim Investigational Site, Riverside, California, United States
🇨🇦
1205.14.145 Boehringer Ingelheim Investigational Site, Sherbrooke, Quebec, Canada

and more 175 locations

Dulcolax vs Placebo in Functional Constipation

Phase 3

Completed

Conditions: Constipation

Interventions: Drug: Bisacodyl 10 mg
Drug: Placebo

First Posted Date: 2007-09-06

Last Posted Date: 2014-01-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 368

Registration Number: NCT00526097

Locations: 🇬🇧
122.56.44011 Boehringer Ingelheim Investigational Site, Bedworth, United Kingdom
🇬🇧
122.56.44032 Boehringer Ingelheim Investigational Site, Addlestone, United Kingdom
🇬🇧
122.56.44018 Boehringer Ingelheim Investigational Site, Ash Vale, Aldershot, United Kingdom

and more 24 locations

Double-blind Trial to Investigate Efficacy and Tolerance of Ambroxol Lozenges 20 mg in Sore Throat

Phase 3

Completed

Conditions: Pharyngitis

Interventions: Drug: Placebo
Drug: Ambroxol

First Posted Date: 2007-09-05

Last Posted Date: 2019-07-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 249

Registration Number: NCT00525044

Locations: 🇨🇳
Boehringer Ingelheim Investigational Site, Wuhan, China
🇨🇳
ENT Subsidiary of Fudan University Hospital, Shanghai, China

Tiotropium In Exercise

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive
Exercise

Interventions: Drug: tiotropium 18 mcg
Drug: Placebo

First Posted Date: 2007-09-05

Last Posted Date: 2013-12-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 519

Registration Number: NCT00525512

Locations: 🇺🇦
205.368.38002 Boehringer Ingelheim Investigational Site, Kiev, Ukraine
🇺🇸
205.368.01008 Boehringer Ingelheim Investigational Site, Fort Collins, Colorado, United States
🇺🇸
205.368.01017 Boehringer Ingelheim Investigational Site, Hartford, Connecticut, United States

and more 59 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy